Cord Blood vs. Cord Tissue: How Stem Cell Types Differ

Cord blood and cord tissue come from the same umbilical cord but contain fundamentally different types of stem cells, serve different medical purposes, and sit at very different stages of clinical maturity. Cord blood is the liquid collected from the umbilical vein after birth and is rich in hematopoietic stem cells, the kind that rebuild blood and immune systems. Cord tissue refers to the solid structure of the cord itself, particularly the gelatinous substance called Wharton’s jelly, which harbors mesenchymal stem cells with broad potential for tissue repair and immune modulation. Understanding what each actually offers, and where each stands in real-world medicine, matters a great deal if you are deciding what to bank or trying to make sense of marketing claims.

What Cord Blood Contains and What It Does

Cord blood collected from the postpartum placenta and umbilical cord is a rich source of hematopoietic stem cells, the cells responsible for producing every type of blood cell in the body: red cells, white cells, and platelets.¹ These cells are more primitive than their counterparts found in adult bone marrow, which gives them higher proliferative capacity and more flexibility in generating different blood cell lines. Research dating back decades established that a single cord blood collection typically contains enough progenitor cells to support the kind of engraftment needed in transplant medicine, making it a viable alternative to bone marrow for reconstituting a patient’s blood and immune system.²

The clinical track record for cord blood transplants is substantial. Cord blood has been used for decades to treat blood cancers like leukemia and lymphoma, inherited blood disorders like sickle cell disease and thalassemia, immune deficiencies, and certain metabolic diseases. One of its standout advantages over bone marrow is a lower rate of graft-versus-host disease, a serious complication in which the donor’s immune cells attack the recipient’s body. A study published in the New England Journal of Medicine found that children receiving cord blood transplants from matched sibling donors had roughly 60% lower risk of acute graft-versus-host disease and about 65% lower risk of chronic graft-versus-host disease compared to those receiving bone marrow.³ In adult transplants comparing cord blood to matched unrelated donor peripheral blood, the incidence of moderate-to-severe chronic graft-versus-host disease at three years was dramatically lower for cord blood recipients.⁴

What Cord Tissue Contains and Where It Stands

Cord tissue, specifically Wharton’s jelly, is the cushioning material that surrounds the blood vessels inside the umbilical cord. It is packed with mesenchymal stem cells, a completely different cell type from the blood-forming cells in cord blood. Mesenchymal stem cells can differentiate into bone, cartilage, fat, and other connective tissue types. They are easy to source, expand well in laboratory culture, and possess immune-modulating properties that make them attractive for a wide range of potential therapies.⁵ Wharton’s jelly mesenchymal stem cells share features with embryonic stem cells in terms of phenotype and gene expression, but they come with a shorter doubling time and greater capacity for expansion outside the body, and they raise none of the ethical concerns associated with embryonic sources.⁶

Clinically, cord tissue mesenchymal stem cells are much earlier in their journey. An analysis of the first decade of clinical trials using these cells (2007–2017) found 178 registered trials and 98 publications. About a fifth of the trials had led to published results, and among those publications, roughly three-quarters reported some form of patient improvement.⁷ That is encouraging, but the field is still building its evidence base. Most applications remain experimental, including trials for autoimmune conditions, liver disease, diabetes, neurological disorders, and orthopedic injuries.

How the Two Types of Stem Cells Differ in Function

The core distinction is not just where the cells come from but what they do once you have them. Hematopoietic stem cells from cord blood are the workhorse of transplant medicine: they engraft in a recipient’s bone marrow and rebuild an entire blood and immune system from scratch. This is what makes cord blood transplants lifesaving for someone with leukemia or a genetic blood disorder. Mesenchymal stem cells from cord tissue do not rebuild blood. Instead, they modulate the immune system and support tissue repair through signaling molecules they secrete.

Research has shown that cord-derived mesenchymal stem cells suppress immune responses primarily through prostaglandin E2, a signaling molecule. When these cells encounter inflammatory signals from the immune system, they ramp up production of prostaglandin E2, which in turn dials down the immune attack.⁸ Pre-treating the cells with inflammatory cytokines can further enhance this immunosuppressive capacity, making them even more potent at inhibiting T cell proliferation.⁹ This is relevant because the therapeutic promise of cord tissue mesenchymal cells leans heavily on their immune-modulating and anti-inflammatory behavior rather than on their ability to directly become replacement tissue.

Animal research has also suggested that co-transplanting mesenchymal stem cells alongside cord blood can enhance the engraftment of the blood-forming cells, with studies showing improved homing of blood stem cells to the bone marrow when mesenchymal cells are present.¹⁰ That finding hints at a future where cord blood and cord tissue cells are used together rather than as an either-or choice, though this combination approach has not yet become standard clinical practice.

Collection and What Affects Quality

Cord blood and cord tissue are collected at the same moment, right after delivery, but the logistics differ. Cord blood is drawn from the umbilical vein using a needle and collection bag. Cord tissue collection involves clamping and cutting a segment of the cord itself, then storing it for later processing. Neither procedure interferes with delivery or poses risk to the mother or baby.

For cord blood, the volume collected is the single strongest predictor of how many usable stem cells you get. Birth weight of the baby and method of delivery also play significant roles.¹¹ Larger babies tend to produce larger cord blood volumes with more stem cells. Cesarean section deliveries tend to yield higher volumes but, counterintuitively, sometimes lower total cell counts per unit volume compared to vaginal delivery.¹² Placental weight and gestational age also influence quality.¹³

One important tension has emerged around delayed cord clamping, which is now widely recommended by obstetric guidelines because it allows more blood to flow from the placenta to the newborn, benefiting the baby’s iron stores. Delaying clamping significantly reduces the amount of blood left for collection. When clamping was delayed more than two minutes, only about 6% of cord blood units had enough cells to meet the threshold for banking, compared to roughly 39% with immediate clamping.¹⁴ This creates a genuine tradeoff: the practice best for the newborn’s immediate health can substantially diminish the banking potential of the cord blood.

Cord tissue collection is less affected by this tradeoff, since you are preserving the physical structure of the cord, not the blood inside it. However, the method used to extract mesenchymal stem cells from the tissue matters. Enzymatic digestion methods can yield higher initial cell counts, but the results vary a lot depending on where along the cord the sample is taken and how long the tissue sat before processing. Explant culture, where small pieces of tissue are placed in a dish and cells migrate out, gives more consistent results across variable conditions.¹⁵

How Pregnancy Conditions Affect Both Sources

Not all cord blood and cord tissue are created equal. Preeclampsia, a serious pregnancy complication involving high blood pressure, has been shown to reduce the quality of both sources. Cord blood from pregnancies complicated by preeclampsia contains significantly fewer hematopoietic stem cells and progenitor cells.¹⁶ The reduced stem cell counts correlate with lower cord blood volume overall, and the progenitor colonies that do form from preeclamptic samples tend to be fewer in number.¹⁷

The cord tissue side is affected too. Mesenchymal stem cells isolated from umbilical cords of preeclamptic pregnancies show reduced proliferation and signs of premature cellular aging, including impaired mitochondrial function.¹⁸ This does not mean cord blood or cord tissue from a preeclamptic pregnancy is worthless, but it is a factor that banking facilities and researchers are aware of.

Banking Decisions and Costs

When families consider banking, the choice is typically between a public bank and a private (family) bank, and between storing cord blood alone, cord tissue alone, or both. Public cord blood banks accept donations at no cost to the family. The donated units become available to any patient worldwide who needs a transplant match. Private banks charge a placement fee, typically in the range of $1,350 to $2,300, plus annual maintenance fees of $100 to $175, in exchange for reserving the sample exclusively for the family.¹⁹ The same policy statement noted that public banks have released thirty times more units for actual clinical use than private banks have, reflecting the statistical reality that any individual family’s stored cord blood unit has a very low probability of ever being needed by that specific child or family.

Cord tissue banking is overwhelmingly a private-bank offering. Public cord blood banks generally do not collect or store cord tissue, because mesenchymal stem cell therapies have not yet reached the level of clinical validation that would justify the infrastructure costs. Private banks actively market cord tissue storage as a form of “biological insurance” against future therapies. This framing is not dishonest, but it does lean on potential rather than proven use. No cord tissue product is currently approved by the FDA for routine clinical use, and the gap between promising early-stage trials and standard-of-care treatment can take many years to cross.

Cryopreservation quality matters for both products. For cord blood, studies have found that stem cells can withstand repeated freeze-thaw cycles without losing their functional capacity when an appropriate slow-freezing protocol is used. Faster freezing protocols, however, can destroy the cells’ ability to form colonies even if they technically appear viable on simple viability tests.²⁰ The takeaway for families evaluating banks: the freezing and storage protocols a bank uses are at least as important as the marketing claims on its website.

Why Cord Blood Has Been a Game-Changer for Underserved Populations

One of the most underappreciated advantages of cord blood over traditional bone marrow transplantation is its impact on access for patients from diverse ethnic backgrounds. Finding a well-matched unrelated bone marrow donor depends heavily on the donor registries, and those registries remain disproportionately composed of people of European descent. In a study of patients undergoing combined searches, fully matched unrelated bone marrow donors were found for about half of patients with European ancestry but only about a fifth of those with non-European origins. By contrast, the majority of both groups had suitable cord blood units available.²¹ Cord blood transplants tolerate a greater degree of mismatch than bone marrow, which substantially widens the pool of usable units. Among transplant recipients in that study, over half of cord blood recipients had non-European ancestry, compared to less than a quarter of bone marrow recipients.

Public cord blood banks have been making deliberate efforts to build more diverse inventories. Canada’s national cord blood bank, launched in 2013, specifically targeted ethnic diversity in its recruitment, and modeling predicted that as the inventory grew, the gap in match likelihood between patients of different backgrounds would progressively narrow.²² This equity dimension is unique to cord blood and does not apply to cord tissue, since mesenchymal stem cell therapies do not require the same degree of immune matching.

How Cord Tissue Mesenchymal Cells Compare to Other Sources

Mesenchymal stem cells can be isolated from many parts of the body: bone marrow, fat tissue, dental pulp, and various regions of the placenta. Not all mesenchymal cells are alike. When researchers compared umbilical cord mesenchymal cells head-to-head with those from different regions of the placenta, cord-derived cells had the fastest growth rate and strong differentiation potential across bone, cartilage, and fat lineages.²³ Cord-derived cells also showed high levels of certain growth factors, and their population doubling time was shorter than that of cells from other placental regions.²⁴ Faster growth translates to more cells in less time, which is critical when you need large numbers for a clinical application.

This practical advantage is a major reason why umbilical cord tissue has become one of the preferred sources for mesenchymal stem cell research. Bone marrow-derived mesenchymal cells require an invasive harvest from the donor and tend to have more limited expansion potential, especially from older donors. Fat-derived cells are abundant but may behave differently. Cord tissue sits in a sweet spot: painless collection, robust growth, strong immune-modulating properties, and no ethical complications.

The Regulatory Landscape and Direct-to-Consumer Marketing

The gap between what cord tissue mesenchymal stem cells might do and what you can actually get treated with today is a source of confusion, partly because of aggressive marketing. A substantial number of businesses in the United States market unapproved stem cell products derived from perinatal sources for conditions ranging from joint pain to neurological disease.²⁵ The FDA has been slow to act against this marketplace. Even after the end of a period of enforcement discretion meant to give companies time to come into compliance, hundreds of businesses continued advertising unapproved stem cell interventions with limited regulatory pushback.²⁶

If a clinic offers you an injection of “cord tissue stem cells” for knee arthritis or anti-aging, it is almost certainly not an FDA-approved treatment. That does not automatically mean the science is baseless, but it does mean you are paying out of pocket for something that has not been through the rigorous trial process required for approval. This is an important distinction from cord blood transplants, which have decades of established clinical use and regulatory standing.

Emerging Research on Cell-Free Therapies From Cord Tissue

Some of the most active research involving cord tissue mesenchymal cells has moved beyond using the cells themselves. Scientists are increasingly interested in exosomes, which are tiny vesicles that mesenchymal cells naturally release. These particles carry proteins, growth factors, and small RNA molecules that can influence the behavior of other cells. The appeal of exosomes is that they offer some of the therapeutic benefits of the parent cells without requiring a live cell transplant, sidestepping concerns about tumor formation or immune rejection.

In heart disease research, exosomes from cord-derived mesenchymal cells have shown cardioprotective effects in animal models of heart attack, working through anti-inflammatory and pro-blood-vessel-growth pathways.²⁷ In wound healing, these exosomes have promoted skin cell growth and new blood vessel formation while reducing inflammation and scarring in animal studies.²⁸ Even in a rat model of severe dry eye disease, exosome treatment reduced corneal damage and lowered inflammatory markers.²⁹ All of this is preclinical, meaning it has been demonstrated in lab dishes and animal models but not yet proven in human patients. Still, the exosome approach represents a potentially important pivot in how cord tissue’s value might ultimately be realized.

Using Cord Blood Stem Cells to Build Immune Therapies

On the cord blood side, one of the newer frontiers involves using hematopoietic stem cells from banked units to manufacture natural killer cells, a type of immune cell that can attack cancer. Researchers at Seattle Children’s have developed a scalable system for generating activated natural killer cells from cord blood stem cells in as little as three weeks, with the goal of producing off-the-shelf immunotherapy products that could treat cancer patients without needing to harvest cells from each individual patient.³⁰ This approach takes advantage of the fact that cord blood cells are immunologically naive and young, making them well-suited raw material for engineering therapeutic immune cells. If this kind of manufacturing scales up successfully, public cord blood banks could become not just a source of transplant units but a feedstock for manufactured cell therapies.